Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: NVO) and Eli Lilly & Co. (NYSE: LLY) grabbed the spotlight. Its stock closed down 18.9% for 2024. However, the medical sector giant recently bounced off three-year lows at $642 in reaction to its fourth quarter of 2024 earnings results.
The company also announced its first-ever dividend and authorized another $3 billion in its stock buyback program. Shares are down 42% from their August 2024 high of $1,211.20. Investors seeking value (deep pullbacks) and growth (upside potential) may want to take a closer look at Regeneron fundamentally and technically.
